Koyfin Home > Directory > Health Care > Horizon Therapeutics > Capital Expenditures

Horizon Therapeutics Capital Expenditures Chart (HZNP)

Horizon Therapeutics annual/quarterly Capital Expenditures from 2010 to 2020.
  • Horizon Therapeutics Capital Expenditures for the quarter ending September 09, 2020 was $-13m a 51.36% decrease of -7m year over year
  • Horizon Therapeutics Capital Expenditures for the last 12 months ending September 09, 2020 was $-140m a 87.24% decrease of -122m year over year
  • Horizon Therapeutics Annual Capital Expenditures for 2019 was $-18m a 73.28% decrease of -13m from 2018
  • Horizon Therapeutics Annual Capital Expenditures for 2018 was $-5m a 9.12% decrease of 0m from 2017
  • Horizon Therapeutics Annual Capital Expenditures for 2017 was $-4m a -262.66% increase of 11m from 2016
Other Cash Flow Metrics:
  • Horizon Therapeutics Cash Flow from Operations for the quarter ending December 12, 2018 was $109m a 155.94% increase of 170m year over year
  • Horizon Therapeutics Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $126m a 125.54% increase of 158m year over year
  • Horizon Therapeutics Total Revenue for the quarter ending December 12, 2018 was $356m a 37.03% increase of 132m year over year
View Chart On Koyfin

Quarterly HZNP Capital Expenditures Data

09/2020$-13m
06/2020$-1m
03/2020$-119m
12/2019$-7m
09/2019$-4m
06/2019$-5m
03/2019$-2m
12/2018$-4m
09/2018$0m
06/2018$0m

Annual HZNP Capital Expenditures Data

2019$-18m
2018$-5m
2017$-4m
2016$-16m
2015$-7m
2014$-4m
2013$-1m
2012$-1m
2011$-2m
2010$-1m